Patents by Inventor Blaise Lippa

Blaise Lippa has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • CCR9 ANTAGONIST COMPOUNDS
    Publication number: 20170216295
    Abstract: Provided herein are compounds that inhibit CCR9 receptor function. Also provided herein are methods of treating inflammatory disease in a subject, comprising administering to the subject a compound of the invention. Accordingly, in one aspect, provided herein is a compound of Formula (1) or a pharmaceutically acceptable salt thereof. In another aspect, provided herein is a pharmaceutical composition, comprising a compound of Formula (1), and a pharmaceutically acceptable carrier.
    Type: Application
    Filed: July 27, 2015
    Publication date: August 3, 2017
    Applicant: Merck Sharp & Dohme Corp.
    Inventors: Bhuamik Pandya, Blaise Lippa, Xin Zhang, Jon Christian Baber, Jan Antionette C. Romero, Jing Zhang
  • AMINE DERIVATIVES USEFUL AS ANTICANCER AGENTS
    Publication number: 20080051419
    Abstract: The invention relates to compounds of formula I: or a pharmaceutically acceptable salt thereof, wherein: A is a moiety of formula: and to pharmaceutically acceptable salts and solvates thereof, wherein X, Z, D, E, V, W, Y, R1, R2, R5, R6, L, and u are as defined herein. The invention also relates to methods of treating abnormal cell growth in mammals by administering the compounds of formula I to a patient in need thereof, and to compositions for treating such disorders which contain the compounds of formula I. The invention also relates to methods of making the compounds of formula I.
    Type: Application
    Filed: July 20, 2007
    Publication date: February 28, 2008
    Inventors: Matthew Corbett, Kevin Freeman-Cook, Goss Kauffman, Blaise Lippa, Michael Luzzio, Joel Morris
  • Byrostatin analogues, synthetic methods and uses
    Publication number: 20070270485
    Abstract: Biologically active compounds related to the bryostatin family of compounds, having simplified spacer domains and/or improved recognition domains are disclosed, including methods of preparing and utilizing the same.
    Type: Application
    Filed: July 3, 2007
    Publication date: November 22, 2007
    Inventors: Paul Wender, Blaise Lippa, Cheol-Min Park, Kevin Hinkle
  • Isothiazole derivatives useful as anticancer agents
    Patent number: 7276602
    Abstract: The invention relates to compounds of the formula 1 or pharmaceutically acceptable salts, prodrugs, solvates or hydrates thereof, wherein wherein X, R1, and R2 are as defined herein. The invention also relates to pharmaceutical compositions containing the compounds of formula 1 and to methods of treating hyperproliferative disorders in a mammal by administering the compounds of formula 1.
    Type: Grant
    Filed: July 24, 2003
    Date of Patent: October 2, 2007
    Assignee: Pfizer Inc
    Inventors: Blaise Lippa, Tricia Ann Kwan, Joel Morris, Susan D. LaGreca, Matthew David Wessel
  • Bryostatin analogues, synthetic methods and uses
    Patent number: 7256286
    Abstract: Biologically active compounds related to the bryostatin family of compounds, having simplified spacer domains and/or improved recognition domains are disclosed, including methods of preparing and utilizing the same.
    Type: Grant
    Filed: February 14, 2003
    Date of Patent: August 14, 2007
    Assignee: The Board of Trustees of the Leland Stanford Junior University
    Inventors: Paul A. Wender, Blaise Lippa, Cheol-Min Park, Kevin W. Hinkle
  • Isothiazole derivatives useful as anticancer agents
    Publication number: 20040152691
    Abstract: The invention relates to compounds of the formula 1 1
    Type: Application
    Filed: July 24, 2003
    Publication date: August 5, 2004
    Applicant: Pfizer Inc
    Inventors: Blaise Lippa, Tricia Ann Kwan, Joel Morris, Susan D. LaGreca, Matthew David Wessel
  • Byrostatin analogues, synthetic methods and uses
    Publication number: 20030220334
    Abstract: Biologically active compounds related to the bryostatin family of compounds, having simplified spacer domains and/or improved recognition domains are disclosed, including methods of preparing and utilizing the same.
    Type: Application
    Filed: February 14, 2003
    Publication date: November 27, 2003
    Inventors: Paul A. Wender, Blaise Lippa, Cheol-Min Park, Kevin W. Hinkle
  • Byrostatin analogues, synthetic methods and uses
    Patent number: 6624189
    Abstract: Biologically active compounds related to the bryostatin family of compounds, having simplified spacer domains and/or imroved recognition domains are disclosed, including methods of preparing and utilizing the same.
    Type: Grant
    Filed: November 30, 2000
    Date of Patent: September 23, 2003
    Assignee: The Board of Trustees of the Leland Stanford Junior University
    Inventors: Paul A. Wender, Blaise Lippa, Cheol-Min Park, Kevin W. Hinkle
  • Byrostatin analogues, synthetic methods and uses
    Publication number: 20020137789
    Abstract: Biologically active compounds related to the bryostatin family of compounds, having simplified spacer domains and/or imroved recognition domains are disclosed, including methods of preparing and utilizing the same.
    Type: Application
    Filed: November 30, 2000
    Publication date: September 26, 2002
    Inventors: Paul A. Wender, Blaise Lippa, Cheol-Min Park, Kevin W. Hinkle